Johnson & Johnson (BUE:JNJ) FFO


BUE:JNJ Johnson & Johnson BUE:JNJ
74 GF Score
Price ARS26,180.00
GF Value ARS19,591.31
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO?

FFO (Funds from operations) only applies to REITs.

BUE:JNJ
74GF Score
Johnson & Johnson BUE:JNJ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (BUE:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of ARS26,180.00 is trading 33.6% above its estimated GF Value™ of ARS19,591.31. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for BUE:JNJ:

  • FFO:
  • GF Value™: ARS19,591.31 vs. price of ARS26,180.00 (33.6% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the BUE:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
74GF Score

Get the complete analysis for BUE:JNJ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS26,180.00
Price
ARS19,591.31
GF Value